BiomX Reports $7.7 Million Net Loss in Q1 2025, Focuses on Clinical Programs

BiomX Inc. reported its financial results for the first quarter of 2025, revealing a net loss of $7.7 million, a significant decrease from the $17.3 million loss recorded in the same period of 2024. The company’s operating loss increased to $7.8 million from $6.8 million year-over-year, primarily driven by higher research and development (R&D) expenses, which rose by 27% to $5.3 million, attributed to preparations for clinical trials and increased costs associated with its diabetic foot osteomyelitis (DFO) program. General and administrative expenses decreased slightly to $2.5 million from $2.7 million, reflecting reduced costs related to the acquisition of Adaptive Phage Therapeutics (APT) in March 2024.

In terms of operational metrics, BiomX's cash and cash equivalents increased to $20.1 million as of March 31, 2025, up from $16.9 million at the end of 2024. The company’s total current assets rose to $23.5 million, while total liabilities decreased to $21.2 million from $23.1 million. The number of shares outstanding increased to 26.2 million, reflecting the issuance of new shares under various financing agreements, including a registered direct offering in February 2025 that raised approximately $5.5 million.

Strategically, BiomX has focused on advancing its clinical programs, particularly its BX004 and BX211 product candidates. The company is preparing to initiate a Phase 2b study for BX004, targeting chronic respiratory infections in cystic fibrosis patients, and has reported positive results from its Phase 2 trial for BX211, which is aimed at treating DFO. The company continues to explore additional funding avenues, including public or private equity, loans, and government grants, to support its ongoing operations and development activities.

Looking ahead, BiomX anticipates that its current liquidity will be sufficient to fund operations into the first quarter of 2026. However, the company acknowledges the need for additional capital to support its growth and development plans, particularly in light of ongoing geopolitical instability in Israel, which could impact its operations. The company remains committed to its research and development efforts, with expectations of continued losses as it advances its clinical programs and seeks to bring its phage-based therapies to market.